Leucine Supplementation Linked to Reduced Lymphoid Malignancy Growth and Improved Survival in Study

A new study identifies hyperthyroidism and membranous nephropathy as significant risk factors for lymphoid malignancies, while highlighting the amino acid leucine as a potential protective agent. Researchers utilized Mendelian randomization and multi-omics data to determine that specific circulating mediators—including promotilin, monounsaturated fatty acids, and glucose—bridge the gap between autoimmune conditions and the development of these cancers. The findings suggest that leucine supplementation may inhibit tumor growth and improve clinical outcomes for patients undergoing treatments such as CAR-T cell therapy.

To reach these conclusions, the research team analyzed data from 10,090 genome-wide association study (GWAS) traits and validated the results using the UK Biobank cohort, which includes over 500,000 participants. Laboratory experiments on lymphoid malignancy cell lines showed that high levels of leucine suppress cancer cell proliferation and trigger apoptosis. In mouse models of B-cell precursor acute lymphoblastic leukemia, dietary leucine supplementation extended survival and reduced symptoms like anemia and thrombocytopenia. Further investigation revealed that leucine functions by reprogramming cell metabolism, specifically by suppressing lipid biosynthesis pathways and reducing the activity of the SREBF1/FASN protein complex. Clinical data from patient cohorts supported these laboratory findings, showing that higher plasma leucine levels correlate with improved survival rates in specific leukemia and lymphoma patients.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: Please provide the content you would like me to format! I am ready to convert your dates into the **Month Day, Year** format.

Author

GOAI